glucagon sold brand name baqsimi among others medication medication used treat low blood sugar beta blocker overdose calcium channel blocker overdose anaphylaxis improve given injection vein muscle version given nose also common side effects include side effects include low blood potassium low blood recommended people pheochromocytoma use pregnancy found harmful glucagon glycogenolytic family works causing liver break glycogen glucagon approved medical use united states world health organizations list essential manufactured form glucagon generic version became available united states december injectable form glucagon may part first aid cases low blood sugar person unconscious reasons take glucose orally intravenous glucagon given intramuscular intravenous subcutaneous injection quickly raises blood glucose levels use injectable form must reconstituted prior use step requires sterile diluent injected vial containing powdered glucagon hormone highly unstable dissolved solution dissolved fluid state glucagon form amyloid fibrils tightly woven chains proteins made individual glucagon peptides glucagon begins fibrilize becomes useless injected glucagon absorbed used body reconstitution process makes using glucagon cumbersome although number products development number companies aim make product easier use anecdotal evidence suggests benefit higher doses glucagon treatment overdose beta blockers likely mechanism action increase camp myocardium effect bypassing βadrenergic second messenger people anaphylaxis beta blockers resistant epinephrine situation glucagon intravenously may useful treat low blood glucagon relaxes lower esophageal sphincter may used impacted food bolus esophagus steakhouse little evidence glucagons effectiveness glucagon may induce nausea considering safety glucagon still considered acceptable option long lead delays arranging glucagons effect increasing camp causes relaxation splanchnic smooth muscle allowing cannulation duodenum endoscopic retrograde cholangiopancreatography ercp procedure glucagon acts quickly common sideeffects include headache nausea drug interactions glucagon interacts oral anticoagulants increasing tendency glucagon used clinically treat various forms hypoglycemia contraindicated patients pheochromocytoma induce tumor release catecholamines leading sudden elevation blood likewise glucagon contraindicated patients insulinoma hyperglycemic effect induce tumor release insulin leading rebound glucagon binds glucagon receptor g proteincoupled receptor located plasma membrane conformation change receptor activates g proteins heterotrimeric protein α β γ subunits g protein interacts receptor undergoes conformational change results replacement gdp molecule bound α subunit gtp molecule substitution results releasing α subunit β γ subunits alpha subunit specifically activates next enzyme cascade adenylate adenylate cyclase manufactures cyclic adenosine monophosphate cyclic amp camp activates protein kinase campdependent protein kinase enzyme turn activates phosphorylase kinase phosphorylates glycogen phosphorylase b converting active form called phosphorylase phosphorylase enzyme responsible release glycogen additionally coordinated control glycolysis gluconeogenesis liver adjusted phosphorylation state enzymes catalyze formation potent activator glycolysis called enzyme protein kinase stimulated cascade initiated glucagon also phosphorylate single serine residue bifunctional polypeptide chain containing enzymes covalent phosphorylation initiated glucagon activates former inhibits latter regulates reaction catalyzing potent activator enzyme primary regulatory step slowing rate formation thereby inhibiting flux glycolysis pathway allowing gluconeogenesis predominate process reversible absence glucagon thus presence insulin glucagon stimulation pka also inactivates glycolytic enzyme pyruvate kimball murlin studied pancreatic extracts found additional substance hyperglycemic properties described glucagon amino acid sequence glucagon described late complete understanding role physiology disease established specific radioimmunoassay developed nasal version approved use united states canada december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product ogluo intended treatment severe hypoglycemia diabetes applicant medicinal product xeris pharmaceuticals ireland limited approved medical use european union february